文献速递精神分裂症与精神病性障碍

首发精神病患者大麻素1受体体内可用性研究

In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

该横断面病例对照研究在芬兰和英国两个独立样本中,采用PET测量首发精神病患者大麻素1受体(CB1R)可用性,发现患者多个脑区CB1R可用性低于匹配对照,且CB1R降低与症状严重程度和认知功能较差相关。

要点

  • 首发精神病患者前扣带回、海马、纹状体和丘脑的CB1R可用性低于匹配对照。
  • 前扣带回CB1R可用性与认知功能正相关,海马CB1R可用性与症状严重程度负相关。
  • CB1R可能是精神病性障碍的潜在治疗靶点。

核心结论

  • 在抗精神病药治疗和未治疗的首发精神病队列中,CB1R可用性均低于匹配对照。
  • 探索性分析提示CB1R水平降低越多,男性患者症状越重、认知功能越差。

研究设计与样本

  • 横断面病例对照研究,包含两个独立样本,分别来自芬兰Turku和英国London的早期精神干预服务。
  • 研究1纳入7例服用抗精神病药的情感性或非情感性精神病患者和11名匹配对照。
  • 研究2纳入20例未使用或未长期使用抗精神病药的精神分裂症或分裂情感性障碍患者和20名匹配对照。
  • 共58名男性纳入分析,对照组平均年龄27.16岁,患者组平均年龄26.96岁。

主要发现

  • 研究1中,[18F]FMPEP-d2分布容积(VT)在组间主效应显著:前扣带回(t16=-4.48,P<.001,Hedges g=1.2)、海马(t16=-2.98,P=.006,Hedges g=1.4)、纹状体(t16=-4.08,P=.001,Hedges g=1.9)、丘脑(t16=-4.67,P<.001,Hedges g=1.4)。
  • 研究2中,[11C]MePPEP VT在组间主效应显著:前扣带回(Hedges g=0.8)、海马(Hedges g=0.5)、纹状体(Hedges g=0.4)、丘脑(Hedges g=0.7)。
  • 患者前扣带回[11C]MePPEP VT与认知功能正相关(R=0.60,P=.01),海马[11C]MePPEP VT与阳性与阴性症状量表总分负相关(R=-0.50,P=.02)。

关键数值与推荐

  • 研究1使用[18F]FMPEP-d2 PET测量CB1R分布容积(VT,单位毫升每立方厘米)。
  • 研究2使用[11C]MePPEP PET测量CB1R分布容积(VT,单位毫升每立方厘米)。
  • 认知功能采用韦氏数字符号编码测验评估。
  • 研究1症状严重程度采用简明精神病评定量表,研究2采用阳性与阴性症状量表。

临床怎么用

  • 首发精神病患者多个脑区CB1R可用性降低,提示CB1R可能参与精神病早期病理生理过程。
  • CB1R可用性降低与症状更重和认知功能更差相关,或可作为潜在治疗靶点。

局限性

  • 样本仅限男性,结果不能外推至女性。
  • 研究为横断面设计,无法确定CB1R改变与精神病发生发展的因果关系。
  • 探索性分析结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown. OBJECTIVE: To investigate CB1R availability in first-episode psychosis (FEP) without the confounds of illness chronicity or the use of illicit substances or antipsychotics. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional, case-control study of 2 independent samples included participants receiving psychiatric early intervention services at 2 independent centers in Turku, Finland (study 1) and London, United Kingdom (study 2). Study 1 consisted of 18 volunteers, including 7 patients with affective or nonaffective psychoses taking antipsychotic medication and 11 matched controls; study 2, 40 volunteers, including 20 antipsychotic-naive or antipsychotic-free patients with schizophrenia or schizoaffective disorder and 20 matched controls. Data were collected from January 5, 2015, through September 26, 2018, and analyzed from June 20, 2016, through February 12, 2019. MAIN OUTCOMES AND MEASURES: The availability of CB1R was indexed using the distribution volume (VT, in milliliters per cubic centimeter) of 2 CB1R-selective positron emission tomography radiotracers: fluoride 18-labeled FMPEP-d2 (study 1) and carbon 11-labeled MePPEP (study 2). Cognitive function was measured using the Wechsler Digit Symbol Coding Test. Symptom severity was measured using the Brief Psychiatric Rating Scale for study 1 and the Positive and Negative Syndrome Scale for study 2. RESULTS: A total of 58 male individuals were included in the analyses (mean [SD] age of controls, 27.16 [5.93] years; mean [SD] age of patients, 26.96 [4.55] years). In study 1, 7 male patients with FEP (mean [SD] age, 26.80 [5.40] years) were compared with 11 matched controls (mean [SD] age, 27.18 [5.86] years); in study 2, 20 male patients with FEP (mean [SD] age, 27.00 [5.06] years) were compared with 20 matched controls (mean [SD] age, 27.15 [6.12] years). In study 1, a significant main effect of group on [18F]FMPEP-d2 VT was found in the anterior cingulate cortex (ACC) (t16 = -4.48; P < .001; Hedges g = 1.2), hippocampus (t16 = -2.98; P = .006; Hedges g = 1.4), striatum (t16 = -4.08; P = .001; Hedges g = 1.9), and thalamus (t16 = -4.67; P < .001; Hedges g = 1.4). In study 2, a significant main effect of group on [11C]MePPEP VT was found in the ACC (Hedges g = 0.8), hippocampus (Hedges g = 0.5), striatum (Hedges g = 0.4), and thalamus (Hedges g = 0.7). In patients, [11C]MePPEP VT in the ACC was positively associated with cognitive functioning (R = 0.60; P = .01), and [11C]MePPEP VT in the hippocampus was inversely associated with Positive and Negative Syndrome Scale total symptom severity (R = -0.50; P = .02). CONCLUSIONS AND RELEVANCE: The availability of CB1R was lower in antipsychotic-treated and untreated cohorts relative to matched controls. Exploratory analyses indicated that greater reductions in CB1R levels were associated with greater symptom severity and poorer cognitive functioning in male patients. These findings suggest that CB1R may be a potential target for the treatment of psychotic disorders.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Borgan F, Laurikainen H, Veronese M, et al. In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. JAMA Psychiatry. 2019. PMID: 31268519. doi:10.1001/jamapsychiatry.2019.1427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。